0
Deep & Emerging Tech·September 7, 2026·1 min read

Insilico, which uses AI to accelerate drug discovery, says early data shows that rentosertib, a drug developed to treat a chronic lung disease, could slow aging

Share

If AI-designed drugs like rentosertib show credible aging effects on top of a primary indication, the upside case for AI-first biotech shifts from faster pipelines to entirely new therapeutic categories. Operators in healthcare need to assume regulators, payers, and ethics boards will become as central a constraint as wet-lab throughput.